Evidence map›Paper›PMID 29855806›Full record

Trial reportMedical oncology (Northwood, London, England)2018

Phase II study of panitumumab combined with capecitabine and oxaliplatin as first-line treatment in metastatic colorectal cancer patients: clinical results including extended tumor genotyping.

George Papaxoinis, Vassiliki Kotoula, Eleni Giannoulatou, Georgia-Angeliki Koliou, Vasilios Karavasilis, Sotirios Lakis, Andreas Koureas, Mattheos Bobos, Elpida Chalaralambous, Emily Daskalaki and 12 more

Abstract readClinical Trial, Phase IIMulticenter Study
PubMed Publisher
In one paragraph

Trial report in Medical oncology (Northwood, London, England), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 9 institutions in 2 countries.

George PapaxoinisOncology Section, Second Department of Internal Medicine, Hippokration Hospital, 11527, Athens, Greece. georgexoinis@gmail.com.ORCID http://orcid.org/0000-0001-6900-784X
Vassiliki KotoulaDepartment of Pathology, Faculty of Medicine, School of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Eleni GiannoulatouVictor Chang Cardiac Research Institute, Darlinghurst, NSW, Australia.
Georgia-Angeliki KoliouSection of Biostatistics, Hellenic Cooperative Oncology Group, Data Office, Athens, Greece.
Vasilios KaravasilisDepartment of Medical Oncology, Faculty of Medicine, School of Health Sciences, Papageorgiou Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Sotirios LakisLaboratory of Molecular Oncology, Hellenic Foundation for Cancer Research/Aristotle University of Thessaloniki, Thessaloniki, Greece.
Andreas KoureasDepartment of Radiology, Aretaieio Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Mattheos BobosLaboratory of Molecular Oncology, Hellenic Foundation for Cancer Research/Aristotle University of Thessaloniki, Thessaloniki, Greece.
Elpida ChalaralambousLaboratory of Molecular Oncology, Hellenic Foundation for Cancer Research/Aristotle University of Thessaloniki, Thessaloniki, Greece.
Emily DaskalakiDepartment of Pathology, Faculty of Medicine, School of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Kyriakos ChatzopoulosLaboratory of Molecular Oncology, Hellenic Foundation for Cancer Research/Aristotle University of Thessaloniki, Thessaloniki, Greece.
George TsironisDepartment of Clinical Therapeutics, Alexandra Hospital, National and Kapodistrian University of Athens School of Medicine, Athens, Greece.
Elisavet PazarliDepartment of Pathology, Faculty of Medicine, School of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Sofia ChrisafiLaboratory of Molecular Oncology, Hellenic Foundation for Cancer Research/Aristotle University of Thessaloniki, Thessaloniki, Greece.
Epaminontas SamantasThird Department of Medical Oncology, Agii Anargiri Cancer Hospital, Athens, Greece.
Ioannis G KaklamanosDepartment of Surgery, School of Health Sciences, General Oncologic Hospital of Kifisia, National and Kapodistrian University of Athens, Athens, Greece.
Ioannis VarthalitisOncology Department, General Hospital of Chania, Crete, Greece.
Athina KonstantaraDepartment of Surgery, St. Luke's Hospital, Thessaloniki, Greece.
Konstantinos N SyrigosOncology Unit GPP, Sotiria General Hospital, National and Kapodistrian University of Athens School of Medicine, Athens, Greece.
George PentheroudakisDepartment of Medical Oncology, Ioannina University Hospital, Ioannina, Greece.
Dimitrios PectasidesOncology Section, Second Department of Internal Medicine, Hippokration Hospital, 11527, Athens, Greece.
George FountzilasLaboratory of Molecular Oncology, Hellenic Foundation for Cancer Research/Aristotle University of Thessaloniki, Thessaloniki, Greece.
Aristotle University of Thessaloniki · GRNational and Kapodistrian University of Athens · GRHippocration General Hospital · GRChania General Hospital ”St. George” · GRHellenic Cooperative Oncology Group · GRHospital Agioi Anargyroi · GRSt. Luke's Hospital · GRUniversity Hospital of Ioannina · GRVictor Chang Cardiac Research Institute · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This clinical trial assessed the efficacy and toxicity of panitumumab combined with oxaliplatin and capecitabine as first-line treatment in KRAS exon 2 wild-type metastatic colorectal cancer (mCRC) patients. Patients with exon 2 KRAS wild-type mCRC received panitumumab 9 mg/Kg, oxaliplatin 130 mg/m

Indexed as

AdultAgedAged, 80 and overAntibodies, MonoclonalAntineoplastic Combined Chemotherapy ProtocolsCapecitabineColorectal NeoplasmsFemaleGenotypeHumansMaleMiddle AgedMutationNeoplasm StagingOrganoplatinum CompoundsOxaliplatinAntibodies, MonoclonalCapecitabineOrganoplatinum CompoundsOxaliplatinPanitumumabTP53 protein, humanTumor Suppressor Protein p53Metastatic colorectal cancerNext generation sequencingPanitumumabTP53Tumor sidedness

Identifiers

PMID29855806
OpenAlexW2807543309

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.